H.C. Wainwright analyst Yi Chen raised the firm’s price target on Clearside Biomedical to $6 from $5 and keeps a Buy rating on the shares. The company reported positive data from the Phase 1/2a OASIS trial of CLS-AX in wet AMD, Chen tells investors in a research note.
Published first on TheFly
See the top stocks recommended by analysts >>
Read More on CLSD:
- Clearside Biomedical Announces Third Quarter 2022 Financial Results and Provides Corporate Update
- Clearside Biomedical Announces Positive Results in Safety, Durability and Biologic Effect in OASIS Phase 1/2a Clinical Trial of Suprachoroidal CLS-AX (axitinib injectable suspension) in Wet AMD Patients
- Clearside Biomedical to Report OASIS Phase 1/2a Clinical Trial Results and Host Conference Call on Wednesday, November 9, 2022 in Conjunction with Third Quarter 2022 Financial Results
- Clearside Biomedical to Report Third Quarter 2022 Financial Results and Provide Corporate Update on Wednesday, November 9, 2022
- Positive Data Presentations at AAO Annual Meeting Demonstrate Utility and Versatility of Clearside Biomedical’s Proprietary Suprachoroidal Space Platform